

Challenges in Implementing a Mobile AI Chatbot

Intervention for Depression Among Youth on Psychiatric

Waiting Lists: A Randomized Control Study Termination

Report

Junichi Fujita^{1,7}, Yuichiro Yano², Satoru Shinoda³, Noriko Sho⁴, Masaki Otsuki⁵, Akira Suda^{6,7}, Mizuho Takayama¹, Tomoko Moroga¹, Hiroyuki Yamaguchi⁷, Mio Ishii⁷, Tomoyuki Miyazaki⁸

1. Department of Child Psychiatry, Yokohama City University Hospital, Yokohama, Japan
2. Department of General Medical Sciences, Juntendo University School of Medicine, Tokyo, Japan
3. Department of Health Data Science, Yokohama City University, Yokohama, Japan
4. Department of Child and Adolescent Psychiatry, Kanagawa Children's Medical Center, Yokohama, Japan
5. Department of Psychiatry, Fujisawa City Hospital, Fujisawa, Japan
6. Psychiatric Center, Yokohama City University Medical Center
7. Department of Psychiatry, Yokohama City University School of Medicine
8. Center for Promotion of Research and Industry-Academic Collaboration, Yokohama City University, Yokohama, Japan

Corresponding author:

Junichi Fujita M.D., Ph.D.

Department of Child Psychiatry, Yokohama City University Hospital

3-9, Fukuura Kanazawa-ku, Yokohama city, 236-0004, Japan

E-mail: jun1182@yokohama-cu.ac.jp

Word count: 4547 words

Abstract

Background The mental health of children and adolescents is a growing public health concern, with increasing rates of depression and anxiety impacting their emotional, social, and academic well-being. In Japan, access to timely psychiatric care is limited, leading to extended waiting periods that can range from three months to a year. AI-driven chatbots, such as emol, which integrate Acceptance and Commitment Therapy (ACT), show potential as digital solutions to support young patients during these waiting times. The AI chatbot emol was selected based on a comprehensive review of Japanese mental health technology applications, including in-person evaluations with company representatives.

Objective This exploratory, parallel-group randomized controlled trial examined the feasibility of using AI chatbot emol with pediatric and adolescent individuals on psychiatric waiting lists.

Methods Participants aged 12-18 years were recruited from four hospitals in Kanagawa Prefecture and randomly assigned to either an intervention group, receiving eight weekly chatbot sessions, or a control group, receiving standard mental health information. The primary outcome was change in Patient Health Questionnaire-9 (PHQ-9) scores from pre- to post-intervention. Secondary assessments, such as voice and writing pressure analysis, provided additional engagement metrics, with data collected at baseline, during the intervention, and at week 9.

Results Of the 96 eligible individuals on psychiatric waiting lists, eight expressed interest, and three provided initial consent. However, all participants subsequently withdrew or were excluded, resulting in no evaluable data for analysis. Low engagement may have been influenced by the perceived irrelevance of digital tools, complex protocols, and privacy concerns.

Conclusions Significant barriers to engagement suggest that digital interventions may need simpler protocols and trusted environments to improve feasibility. Future studies could test these interventions in supportive settings, like schools or community centers, to enhance accessibility and participation among youth.

Trial Registration: Japan Registry of Clinical Trials (jRCT) jRCT1032230427

Keywords: randomized controlled trial; AI chatbot; acceptance and commitment therapy; mental health; psychiatry; children; adolescents; Japan

INTRODUCTION

Depression and anxiety in children and adolescents are increasingly recognized as significant public health issues, profoundly affecting their emotional, social, and academic development[1,2]. Early intervention is crucial, as untreated depressive symptoms in youth are associated with a higher risk of recurrent episodes in adulthood [3]. Despite the growing demand for effective treatments, access to child and adolescent psychiatric services remains limited due to resource shortages, resulting in extended waiting periods for consultation worldwide [4]. In Japan, the waiting time for child and adolescent mental health services averages from three months to one year, and these delays have worsened due to rising demand for mental health care [5]. At Yokohama City University Hospital, for example, as of October 2023, the waiting time for appointments was 8 months, with over 120 patients aged 12-18 years on the psychiatric waiting list. The impact of the COVID-19 pandemic has further aggravated the mental health of young individuals globally, with rates of depression and anxiety among children and adolescents approximately doubling compared to pre-pandemic levels [6] . The increasing prevalence of adolescent depression and prolonged waiting periods for psychiatric care present urgent challenges in mental health service delivery. For young patients on waiting lists, the lack of timely intervention can exacerbate symptoms and increase the risk of severe outcomes, such as self-harm, suicide attempts, or psychotic experiences[7, 8].

Cognitive behavioral therapy (CBT), such as Acceptance and Commitment Therapy (ACT) is a first-line treatment for depression and anxiety in young people, yet barriers such as limited availability of trained therapists highlight the need for alternative delivery methods [9] . Digital health technologies, including AI-driven chatbots, offer an innovative approach to bridge the gap between service demand and supply. Existing studies have shown that internet-delivered CBT can be as effective as therapist-delivered CBT for treating depressive symptoms in children and adolescents [10] . Preliminary research on AI chatbots has demonstrated significant reductions in depression and anxiety among young users, underscoring the potential of these digital tools[11, 12].

Despite the growing interest in digital mental health interventions, there is limited research on the effectiveness of AI chatbots specifically for children and adolescents awaiting psychiatric consultation. Although prior studies have highlighted the potential benefits of AI chatbots in reducing depressive symptoms[13], these interventions have not been systematically tested among high-need populations, such as youth on psychiatric waiting lists. Given the prevalence of depressive symptoms among pediatric psychiatric patients and the potential for severe consequences, timely intervention is crucial[7, 8]. By offering mental health support through accessible digital devices like

smartphones, the AI chatbot enables pre-consultation care that can be implemented in various settings, including schools. This approach could facilitate early intervention and support, providing a bridge until professional care becomes available and making mental health resources more accessible to young individuals outside traditional clinical environments.

Japan has a growing number of mental health technology applications, including various AI-driven chatbots, as outlined in recent market analyses. Several AI chatbots for mental health care have demonstrated reasonable feasibility, acceptability, and potential usefulness in Japan [14, 15]; however, few have been developed specifically for children and adolescents. For example, AI chatbot emol, developed in Japan, offers structured, ACT-based interventions through an accessible, engaging interface tailored for youth. By leveraging its therapeutic design and user-friendly features [16], it provides interim support to adolescents awaiting professional care.

We hypothesized that using the AI chatbot would significantly improve depressive symptoms and reduce clinical symptoms among children and adolescents on psychiatric waiting lists compared to standard care, thus enhancing mental health outcomes during the waiting period. The purpose of this study was to evaluate the effectiveness of the AI chatbot in improving depressive symptoms during the waiting period for children and adolescents on waiting lists, as a preliminary phase. The primary aims were to estimate the data acquisition rate and dropout rate in the intervention group, and to estimate the difference in depressive symptom change between the intervention and control groups before and after the intervention, to validate case number calculations for the next randomized controlled trial (RCT).

METHODS

Study Design

This exploratory, parallel-group, randomized controlled trial assigned participants to either an intervention group using the AI chatbot or a control group receiving standard care.

Participants were centrally randomized by Nouvell Plus Inc. using a minimization method based on baseline PHQ-9 scores and gender to prevent significant imbalance. Blinding was not implemented as it was deemed unnecessary for the intervention.

Recruitment materials explicitly stated that the study was conducted by researchers from Yokohama City University. This information was included on printed leaflets distributed to potential

participants. The affiliation was presented to enhance credibility but may also have influenced participant expectations and willingness to enroll. Participants were briefed about the study objectives, procedures, and potential risks through an online recruitment session. Written informed consent was obtained from both participants and guardians before enrollment. The informed consent documentation is available in the appendix for transparency.

No changes to the trial methods, including eligibility criteria, were made after trial commencement.

AI Chatbot Selection Process

To identify the most suitable AI chatbot for supporting adolescents on psychiatric waiting lists, a comprehensive evaluation of existing mental health applications in Japan was conducted. The selection process involved the following steps:

1. Comprehensive Review of Applications

Publicly available AI-driven mental health chatbots were reviewed for their therapeutic frameworks, usability, and relevance to adolescents. Special consideration was given to apps incorporating evidence-based treatments such as Acceptance and Commitment Therapy (ACT).

2. In-Person Evaluation with Developers

Developers of shortlisted chatbots were interviewed to gain deeper insights into app features, target audiences, and implementation strategies.

3. Selection Criteria

Chatbots were evaluated based on the following criteria:

- Integration of evidence-based therapeutic frameworks (e.g., ACT).
- Accessibility and ease of use for adolescents.
- Engagement-focused design, including gamified elements or interactive interfaces.

Compatibility with the study's requirements for digital interventions in clinical settings.

Finally, the AI chatbot emol, developed by Emol Inc. and released in March 2018, was selected for its integration of Acceptance and Commitment Therapy (ACT), an evidence-based

treatment for depression and anxiety. The chatbot was developed in collaboration with clinical psychologists and researchers to integrate ACT based principles. The chatbot includes features such as conversational AI, emotional logging, interactive exercises, gamification elements, and monitoring tools to support user engagement. This therapeutic approach enables AI chatbot emol to offer targeted, structured interventions, distinguishing it from chatbots with less comprehensive therapeutic frameworks. The user interface employs a minimalist design, with simple text-based interactions and no external hyperlinks. Content was developed in collaboration with clinical psychologists and researchers at Emol Inc., ensuring alignment with ACT based principles. The chatbot provides asynchronous communication, allowing users to engage at their convenience without requiring real-time interaction.

AI chatbot emol's design prioritizes accessibility and engagement, particularly for young users, by featuring a friendly AI character named "Roku." AI chatbot emol features a friendly character named "Roku," who guides users through ACT-based conversations in a relatable manner. The chatbot provides asynchronous communication, allowing participants to engage at their convenience. Sessions are pre-programmed to follow a consistent instructional strategy, beginning with a mood check-in and concluding with goal-setting exercises. Additional features, such as emotional logging and sleep tracking, allow users to actively monitor their mental health. AI chatbot emol's comprehensive approach to digital mental self-care makes it especially well-suited for adolescents, who may prefer digital interactions over traditional therapy. By offering an approachable alternative for managing mental health challenges, AI chatbot emol has the potential to fill a critical gap in mental health service delivery for young people awaiting professional care (<https://emol.jp/>).

However, no formal feasibility or usability studies have been conducted specifically for children and adolescents awaiting psychiatric consultation. The selection of emol for this study was based on a comprehensive review of Japanese mental health technology applications and direct discussions with the developers.

In this study, Emol Inc. provided the AI Chatbot emol at a discounted rate. This is disclosed in the Conflict of Interest section.

Participants

Participants in this study were individuals on the psychiatric waiting list for Yokohama City

University Hospital, Yokohama City University Medical Center, Kanagawa Children's Medical Center, and Fujisawa City Hospital, all four hospitals located in the south-eastern region of Kanagawa Prefecture. Those were aged between 12 and 18 years at the time of enrollment. These hospitals play a central role in child psychiatric services in the eastern part of Kanagawa Prefecture, Japan. As of January 2024, the population of 10-19-year-olds in Kanagawa Prefecture was estimated to be 774,283 [17] .

The recruitment period was planned to span from October 1st, 2023, to September 30th, 2024, allowing sufficient time to ensure robust participant enrollment and data collection.

Inclusion and Exclusion Criteria

The inclusion criteria were as follows: 1) a score of 10 or higher on the Patient Health Questionnaire-9 (PHQ-9), indicating clinical depressive symptoms; 2) access to a device capable of running AI chatbot emol; 3) access to online interviews via Zoom (Zoom Inc.); 4) proficiency in reading and writing Japanese at the upper elementary school level; and 5) agreement to abstain from using other mental self-care apps during the study period.

The exclusion criteria were as follows: 1) patients deemed to require urgent care by a child psychiatrist; 2) patients reporting a suicide attempt within the past two weeks on their screening questionnaire, or patients in urgent need of physical treatment due to conditions such as anorexia; 3) patients who had received treatment at another psychiatric facility within the past month or who expressed a desire for future treatment at such a facility; 4) patients who were continuing to take psychotropic medications prescribed by the above-mentioned facilities; and 5) patients unable to complete diaries due to physical issues such as injury.

Intervention Group

The intervention group received general mental health information via the Yokohama City University child psychiatry department's website, "Oyako-no Kokoro-no Tomarigi" (<http://www-user.yokohama-cu.ac.jp/~ycucap/>), which provides short video programs related to mental health care.

Additionally, eight weekly sessions were provided by the AI chatbot emol. Each session lasted between 20 to 30 minutes (<https://emol.jp/>). No major bug fixes, system downtimes, content

changes, or unexpected events occurred during the trial that could have influenced the intervention's functionality or delivery. During the trial period, the version of emol remained unchanged, and no major content updates, feature modifications, or dynamic content changes occurred. The intervention was evaluated as a stable version, ensuring the replicability of study findings. The intervention can be accessed at the website (<https://emol.jp/>). While the current version reflects the intervention used in this study, future changes may occur. To ensure replicability, screenshots and videos of the interface are available upon request from the developers. Participants accessed the AI chatbot emol via their personal smartphones. All participants needed to have a stable internet connection and a device capable of running the application. Access to the chatbot was restricted to study participants only, and no public demo mode was available. However, a free version of the emol program, which differs from the study version, is publicly available at the website (<https://emol.jp/>) . Participants were not required to pay any fees for accessing the chatbot during the study. A stable internet connection and a compatible device were necessary for access. No critical secular events, such as changes in internet resources or hardware requirements, occurred during the study period.

The session overview in AI chatbot emol included the following:

Session 1: Distress and suffering

Session 2: Avoidance of experiences

Session 3: Control over what can be managed

Session 4: Acceptance

Session 5: Observing from a detached perspective

Session 6: Life values

Session 7: Commitment

Session 8: Continuation of commitment

Weekly online assessments were conducted at Week 0, during the intervention period, and at Week 9. Weekly online assessments were conducted at Week 0, during the intervention period, and at Week 9. Non physician research assistants encouraged participants to use the pen consistently for their diary entries and performed minimal mental status checks during these assessments. No

additional co-interventions, training sessions, or structured support were provided beyond these assessments. For routine application outside of the RCT setting, no training is required for users. No automated prompts or reminders were used during the trial or for routine application outside of the RCT setting. The periodic assessments were administered by non-physician research assistants, who performed minimal mental status checks and checked assessment items such as PHQ-9, Athens Insomnia Scale (AIS), and adverse events. Simultaneously, non-physician research assistants saved recorded audio data for voice analysis. They also provided technical assistance when required. Human support was limited to assessment and monitoring during the intervention, with no direct involvement in the therapeutic process. For routine application outside of the RCT setting, no human involvement would be required. For measuring writing pressure, participants were provided with an intelligent pen pressure device developed by ZEBRA HOLDINGS Inc. and given a diary in which they recorded the date, time, weather, and mood (options included "good," "normal," or "bad") within two hours of waking. Research assistants encouraged participants to use the pen consistently for their diary entries.

Control Group

The control group received general mental health information via the Yokohama City University child psychiatry department's website, "Oyako-no Kokoro-no Tomarigi" (<http://www-user.yokohama-cu.ac.jp/~ycucap/>), similar to the intervention group. Participants in the control group also underwent the same regular online evaluations and diary recording process as those in the intervention group.

Criteria for Discontinuation

The criteria for discontinuing the intervention for individual participants were as follows:

- 1) Withdrawal of consent by the participant or their legal representative
- 2) Determination that the participant no longer met the inclusion criteria or met any exclusion criteria post-enrollment
- 3) Worsening of symptoms or findings that made study continuation challenging
- 4) Occurrence of adverse events that posed challenges to study continuation
- 5) Initiation of additional treatments, such as psychiatric care, counseling, or use of mental health applications

- 6) A determination by the principal investigator or sub-investigator that continuation was otherwise undesirable

The criteria for study termination were as follows:

- 1) Determination that the study intervention lacked expected efficacy, posed safety concerns, or was no longer meaningful to continue
- 2) Significant delays in case registration, frequent protocol deviations, or other factors that made study completion difficult
- 3) Occurrence of serious compliance issues affecting study execution.

Primary Outcome

The primary outcome was the change in PHQ-9 scores from pre- to post-intervention. This measure was selected because assessing treatment efficacy through PHQ-9 score changes is commonly recommended and widely accepted in clinical research, including in Japan [18]. The PHQ-9, a self-administered questionnaire consisting of nine items, evaluates the presence and severity of depressive symptoms based on DSM-IV criteria for major depressive disorder within the past two weeks. The total PHQ-9 score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms. The PHQ-9 score obtained at Week 0 was used as the baseline.

Secondary Outcomes

The secondary outcome measures evaluated the correlation and relationship between changes in the primary outcome measure (PHQ-9) and the following items:

• *AIS*

The AIS is a self-assessment tool developed as part of the World Health Organization's (WHO) "World Project on Sleep and Health" to evaluate insomnia with high reliability and validity [19]. The scale includes eight items, with five assessing nighttime sleep difficulties ("sleep onset," "nighttime awakenings," "early morning awakenings," "sufficiency of total sleep duration," and "satisfaction with sleep quality") and three evaluating daytime functional impairment ("daytime mood," "daytime activity level," and "daytime sleepiness"). Participants rated the frequency of these experiences (at least three times a week in the past month) on a 4-point scale. A total score of 4 or

more suggested suspected insomnia, while a score of 6 or more indicated insomnia.

• *Voice Analysis*

During online consultations, participants' voices were recorded while they conversed with the interviewer. Voice data was analyzed by SHIN4NY Inc., with recordings provided to the company for analysis. A previous study demonstrated that a speech emotion recognition model could predict depression [20] .

• *Writing Pressure Analysis*

Upon providing consent, participants received a diary and instructions on how to record entries using an intelligent pen pressure device developed by ZEBRA HOLDINGS Inc. This device, a mechanical pencil, automatically captured data on writing pressure, acceleration, and pen angle, storing it without requiring additional action from the participant. Previous research has suggested that an intelligent pen capable of measuring writing pressure may predict anxiety levels [21] .

These data were collected at baseline (Week 0), during the intervention, and at the study's conclusion (Week 9) through online consultations. Evaluations included PHQ-9, AIS, voice analysis, and intelligent pen pressure device data.

Data Management

Data entry was conducted by research assistants and verified by the principal investigator. A data dictionary guided the coding process, and central monitoring took place once during the study period based on the collected case report forms.

Statistical Analysis

The analysis populations were defined as follows, with the primary analysis population being the Full Analysis Set (FAS). This study included all participants who were registered, randomized, received at least one session of the trial intervention, and had available efficacy data. Participants were excluded if baseline data were not obtained or if significant protocol violations occurred. Additionally, the FAS included participants who had no major deviations from the study protocol. Missing data were addressed by the predefined statistical analysis plan, with the primary analysis conducted on the FAS.

The target sample size for the study was 60 participants (30 in each group). This calculation assumed an expected between-group mean difference in PHQ-9 change scores of 7, a standard deviation of 10, a two-sided significance level of 0.10, and a power of 0.80, using an independent two-sample t-test. The estimated sample size was 26 participants per group, and a target of 30 participants per group was set to allow for possible exclusions.

The primary analysis was conducted using the FAS. Changes in PHQ-9 scores from pre- to post-intervention were presented as the mean \pm standard deviation. An analysis of covariance (ANCOVA) estimated the difference between groups, including the 90% confidence interval and p-value for the group comparison. A two-sided test was used, with statistical significance determined at $p < 0.10$. The secondary analysis was conducted on the Per Protocol Set (PPS) using the same summary and analytical methods as the primary analysis.

Ethical Considerations

This study was registered with the Japan Registry of Clinical Trials (jRCT) under registration number jRCT1032230427. The full trial protocol is available at the jRCT website: <https://jrct.niph.go.jp/re/reports/detail/86750>. Approval for the study was granted by the Ethics Committee of Yokohama City University (Approval number F230907001). All procedures were conducted in accordance with the ethical standards outlined in the Declaration of Helsinki and the "Ethical Guidelines for Medical and Health Research Involving Human Subjects." Written informed consent was obtained from both participants and their guardians before enrollment. When possible, assent from participants was also sought; if direct assent was difficult to obtain, informed assent was acquired as an alternative. Participant privacy and confidentiality were strictly protected, and data collected was used solely for research purposes. All personal information was handled in accordance with Yokohama City University's Privacy Policy (<https://www.yokohama-cu.ac.jp/policy/privacy.html>). Findings from the study are to be disseminated through peer-reviewed journals and academic conferences.

Protocol Version and Amendments

Protocol Version 1 was initially approved on September 27, 2023, with Version 2 subsequently approved on February 15, 2024.

RESULTS

This study was conducted across four hospitals in Kanagawa Prefecture: Kanagawa Children's Medical Center, Fujisawa City Hospital, Yokohama City University Hospital, and Yokohama City University Medical Center, targeting pediatric and adolescent psychiatric patients awaiting consultation. Recruitment materials were distributed from October 2023 to June 2024 for waiting list patients at each hospital as follows:

Kanagawa Children's Medical Center: 78 patients

Fujisawa City Hospital: 8 patients

Yokohama City University Hospital: 10 patients

Yokohama City University Medical Center: 0 patients

A total of 96 patients received study invitations (78 from Kanagawa Children's Medical Center, 8 from Fujisawa City Hospital, and 10 from Yokohama City University Hospital). Of these, 8 patients expressed interest by contacting us for additional information. Out of those who expressed interest, three patients scheduled and completed the informed consent (IC) process, while the remaining 5 did not proceed with IC due to lack of response when attempting to arrange a schedule.

Among the three patients who completed the IC process, only 1 provided consent but subsequently withdrew from the study due to worsening psychiatric symptoms. Another patient declined participation due to concerns about diary recording, and the third patient was excluded after beginning medication at another facility. Consequently, no evaluable data was obtained in this study.

DISCUSSION

The primary finding of this study - that children and adolescents with mental health challenges and their caregivers showed limited interest in an AI chatbot-based intervention while awaiting psychiatric consultation - highlights complex barriers to the adoption of digital mental health interventions. Several factors contributed to this low engagement. In this study, only one participant consented but subsequently withdrew due to a worsening of symptoms. This outcome suggests that patients with more severe symptoms may find digital interventions less suitable or accessible. However, given the need for timely intervention among high-severity cases, it is worth exploring

ways to make AI-driven tools like chatbots more adaptable to their needs. Improving the usability and support level of digital tools for more severe cases could provide valuable early intervention options where in-person resources are limited.

First, many young patients, particularly those who have not received a formal diagnosis or treatment, may struggle to understand the relevance of app-based mental health support and may not fully appreciate its therapeutic value, especially when compared to the immediate effects associated with in-person interventions like pharmacotherapy or face-to-face therapy. A previous study with small sample sizes has shown that AI chatbot app dropouts for psychogenic premature ejaculation were only around 25% among Japanese adults [22] . On the other hand, previous studies suggest that young patients often lack intrinsic motivation to engage with mental health apps, especially when their symptoms are severe enough to require professional care [23, 24] . Additionally, research indicates that more personalized support may be essential for individuals with severe symptoms [25] . Without a clear understanding of the intervention or trust in its benefits, these young patients may lack motivation to use the app consistently, contributing to low engagement in the study.

This study may have unintentionally targeted a population less receptive to alternative digital interventions. Families who had already secured an upcoming psychiatric appointment may have seen little value in participating in a study involving digital interventions, preferring instead to wait for their scheduled in-person consultation. For these families, traditional in-person care may have appeared more reassuring, especially given the severity of the patient's symptoms. Previous research on social influences in mental health service-seeking behavior among young people suggests that family is often the primary influence in choosing in-person services, whereas young people themselves tend to make decisions regarding online services [26] . Another study has also found that parents often seek informal support for their children's mental health concerns initially, only turning to professional services as issues become more severe [27] . Additionally, patients with severe symptoms or their families often prefer in-person consultations over digital interventions, perceiving in-person care as more reliable and suitable for managing serious symptoms [28] . Therefore, patients and families may value the familiarity and perceived efficacy of traditional, in-person care as a more reliable or reassuring option compared to digital alternatives. This preference likely contributed to the reluctance toward digital solutions observed in this study. Engaging patients and families earlier in the mental health care process—before they have secured traditional clinical appointments—might improve receptiveness to digital options.

Furthermore, our study protocol involved multiple evaluation sessions, which could have imposed additional stress on participants, particularly those with social anxiety or other issues related to interpersonal interactions. A previous study of AI chatbot, with relatively low dropout rate was simple, focusing solely on the use of the app without requiring additional interventions or assessments [15] . Previous studies indicate that such requirements can increase dropout rates, especially among adolescents with social phobia [29, 30] . In this context, the protocol's demands may have discouraged participation and contributed to low engagement. Although efforts were made to reduce participant burden by conducting interviews online, the process of obtaining informed consent and providing detailed study information likely remained a challenge for some participants, especially those who may be sensitive to social interactions.

Lastly, secondary assessment methods like voice and writing pressure analysis may have caused some participants to feel self-conscious or concerned about privacy, potentially exacerbating symptoms or causing reluctance to participate [31] . Privacy concerns are common with mental health apps, especially when personal data is analyzed, and this may affect user engagement [32] . In this study, participants may have felt uneasy about the voice recordings or writing pressure data being analyzed, as well as discussing their mental health status with researchers. These issues may have created additional barriers to engagement, particularly for young people unfamiliar with research environments. In the current study design, the exclusion of severe cases and the online interview assessment to reduce the burden of face-to-face implementation may not have been sufficient.

Strengths and Limitations

This study had both methodological strengths and limitations. Conducting a randomized controlled trial in an understudied population—children and adolescents on psychiatric waiting lists—provided valuable insights into a critical phase of mental health service delivery, and the exploratory nature of the trial allowed for close examination of data acquisition and dropout rates. Additionally, our use of multiple assessment methods enabled a comprehensive evaluation of potential therapeutic effects and engagement patterns, which is rare in digital mental health studies involving youth.

However, the intensity of the intervention, including frequent evaluations and a structured protocol, may have been overwhelming for participants. This study suggests that less rigid protocols with fewer demands could enhance engagement. Additionally, recruiting patients already awaiting

traditional psychiatric care may have reduced openness to digital alternatives, thus limiting the generalizability of our findings. Targeting a population that has not yet committed to in-person care—such as students in school counseling or those referred by community organizations—may address this issue in future studies. Finally, while secondary measures such as voice and writing pressure analysis provide valuable data, they may also create privacy concerns that deter participation, particularly among younger users. Additionally, typical limitations of eHealth trials should be noted. Participants were not blinded, which may have introduced performance bias. The informed consent process could have influenced their expectations, and the multiple outcomes planned for the study could have increased the risk of Type I errors. Future studies should address these biases and explore strategies to improve participant engagement.

Future Directions for Research

To better understand the potential of AI chatbot interventions like “emol,” future studies could test the app in environments where supportive, pre-existing relationships exist, such as schools or community youth centers. Conducting trials in these familiar settings may foster trust, encourage participation, and enhance data validity, ultimately increasing the accessibility and effectiveness of digital mental health interventions for young people.

Acknowledgments

We would like to express our gratitude to the following individuals for their invaluable support in this study. Minori Ito assisted with participant recruitment and study-progress management as research assistant. Mikiko Yuzawa from Nouvelle Plus Inc. managed the data center and prepared the ethics application documents. Yasuyuki Okumura from Initiative for Clinical Epidemiological Research provided support in developing the research plan. We also thank Daiki Takekawa from Emol Inc., Eiji Okuno from ZEBRA HOLDINGS Inc., and Kanji Okazaki from SHIN4NY Inc. for their contributions in providing devices and support from their respective companies. We also acknowledge the assistance of OpenAI's ChatGPT and Anthropic's Claude in supporting the drafting and English editing process of this manuscript.

Conflict of interest disclosure

This study was supported by the Japan Science and Technology Agency (JST) Grant Number JPMJPF1234. The funder had no role in study design, data collection, analysis, interpretation, or manuscript submission decisions. SS, NS, MO, MI, MT, HY, MT, TM have no conflict of interest. Individually, JF received research grants from KAKENHI (21K01994). JF also served as a member of an advisory board for Seisa Yokohama Educational Counseling Center. YY received consulting fees from ZEBRA HOLDINGS Inc.

In this study, Emol Inc. provided the AI Chatbot emol at a discounted rate, ZEBRA HOLDINGS Inc. contributed research funding, and SHIN4NY Inc. offered devices at a reduced cost. This study was funded by the Japan Science and Technology Agency (JST) under the Co-creation Opportunity Formation Support Program (COI-NEXT), FY2022–2031. The supporting companies and the funding agency had no role in study design, data collection, analysis, interpretation, or manuscript submission decisions.

References

- 1) de Lijster JM, Dieleman GC, Utens EMWJ, Dierckx B, Wierenga M, Verhulst FC, et al. Social and academic functioning in adolescents with anxiety disorders: a systematic review. *J Affect Disord* 2018;230:108-117. PMID:29407537 doi:10.1016/j.jad.2018.01.008
- 2) Verboom CE, Sijtsma JJ, Verhulst FC, Penninx BWJH, Ormel J. Longitudinal associations between depressive problems, academic performance, and social functioning in adolescent boys and girls. *Dev Psychol* 2014;50(1):247-257. PMID:23566082 doi:10.1037/a0032547
- 3) Davey CG, McGorry PD. Early intervention for depression in young people: a blind spot in mental health care. *Lancet Psychiatry* 2019;6(3):267-272. PMID:30477927 doi:10.1016/S2215-0366(18)30292-X
- 4) Kaku SM, Sibeoni J, Basheer S, Chang JP-C, Dahanayake DMA, Irarrazaval M, et al. Global child and adolescent mental health perspectives: bringing change locally, while thinking globally. *Child Adolesc Psychiatry Ment Health* 2022;16:82. PMID:36153528 doi:10.1186/s13034-022-00512-8
- 5) Toyo Keizai education × ICT Editorial Department. The increase in developmental disorders lengthens "waiting times for initial pediatric psychiatric consultations"; a serious shortage of doctors. *Toyo Keizai Online*. 2023 Sep 11. URL: <https://toyokeizai.net/articles/-/698503> [accessed 2024-01-15]
- 6) Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S. Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: a meta-analysis. *JAMA Pediatr* 2021;175(11):1142-1150. PMID:34369987 doi:10.1001/jamapediatrics.2021.2482
- 7) Hawton K, Saunders KE, O'Connor RC. Self-harm and suicide in adolescents. *Lancet* 2012;379(9834):2373-2382. PMID:22726518 doi:10.1016/S0140-6736(12)60322-5
- 8) Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. *JAMA Psychiatry* 2018;75(6):555-565. PMID:29800949 doi:10.1001/jamapsychiatry.2018.0623
- 9) Nakao M, Shirotaki K, Sugaya N. Cognitive-behavioral therapy for management of mental health and stress-related disorders: recent advances in techniques and technologies. *BioPsychoSoc Med* 2021;15:16. PMID:34526127 doi:10.1186/s13030-021-00217-2
- 10) Andrews G, Basu A, Cuijpers P, Craske MG, McEvoy P, English C, et al. Computer therapy for

the anxiety and depression disorders is effective, acceptable and practical health care: a meta-analysis. PLoS ONE 2018;13(2):e0192188. PMID:29451092

doi:10.1371/journal.pone.0192188

- 11) Fitzpatrick KK, Darcy A, Vierhile M. Delivering cognitive behavior therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (Woebot): a randomized controlled trial. JMIR Ment Health 2017;4(2):e19. PMID:28588005
doi:10.2196/mental.7785
- 12) Fulmer R, Joerin A, Gentile B, Lakerink L, Rauws M. Using psychological artificial intelligence (Tess) to relieve symptoms of depression and anxiety: randomized controlled trial. JMIR Ment Health 2018;5(4):e64. PMID:30545815 doi:10.2196/mental.9782
- 13) Zhong W, Luo J, Zhang H. The therapeutic effectiveness of artificial intelligence-based chatbots in alleviation of depressive and anxiety symptoms in short-course treatments: a systematic review and meta-analysis. J Affect Disord 2024;356:459-469. PMID:38090065
doi:10.1016/j.jad.2024.04.057
- 14) Kamita T, Matsumoto A, Ito T, Inoue T. Development and evaluation of a chatbot system for self-guided mental healthcare based on the SAT counseling method. IPSJ SIG Technical Report 2020;2020-DCC-25(4):1-8. URL: <https://www.ipsj.or.jp> [accessed 2024-01-15]
- 15) Saito J, Kumano H, Ghazizadeh M, Shimokawa C, Tanemura H. An Acceptance and Commitment Therapy smartphone application for erectile dysfunction: a feasibility study. Curr Ther Res 2023;99:100728. PMID:37094049 doi:10.1016/j.curtheres.2023.100728
- 16) emol Inc. Japan's 2023 mental health tech chaos map released! Establishment of the Mental Health Tech Research Association. PR TIMES. 2023 Jun 19. URL: <https://prtimes.jp/main/html/rd/p/000000017.000043787.html> [accessed 2024-01-15]
- 17) Kanagawa Prefecture. (2024). Report on age-specific population statistics of Kanagawa Prefecture: As of January 1, 2024 (Estimated population based on the 2020 national census results). Retrieved from Kanagawa Prefecture Press Release website: <https://www.pref.kanagawa.jp>
- 18) Muramatsu, K., Miyaoka, H., Kamijima, K., Muramatsu, Y., Tanaka, Y., Hosaka, M., et al. (2018). Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care. General Hospital Psychiatry, 52, 64-69.
<https://doi.org/10.1016/j.genhosppsy.2018.03.007>
- 19) Okajima, I., Nakajima, S., Kobayashi, M., & Inoue, Y. (2013). Development and validation of the Japanese version of the Athens Insomnia Scale. Psychiatry and Clinical Neurosciences, 67(6), 420-425. <https://doi.org/10.1111/pcn.12073>

- 20) Hansen L, Zhang Y-P, Wolf D, Sechidis K, Ladegaard N, Fusaroli R. A generalizable speech emotion recognition model reveals depression and remission. *Acta Psychiatr Scand* 2022;145(2):186-199. PMID:34791663 doi:10.1111/acps.13388
- 21) Tapia-Jaya, C., Ojeda-Zamalloa, I., Robles-Bykbaev, V., Pesántez-Avilés, F., San Andrés Becerra, I., et al. (2017). An intelligent pen to assess anxiety levels through pressure sensors and fuzzy logic. In *Advances in Human Factors in Wearable Technologies and Game Design* (pp. 64-71). AHFE 2017. *Advances in Intelligent Systems and Computing*, 608.
https://doi.org/10.1007/978-3-319-60639-2_7
- 22) Saito, J., Kumano, H., Ghazizadeh, M., Shimokawa, C., & Tanemura, H. (2023). An Acceptance and Commitment Therapy smartphone application for erectile dysfunction: A feasibility study. *Current Therapeutic Research*, 99, Article 100728.
<https://doi.org/10.1016/j.curtheres.2023.100728>
- 23) Garrido S, Oliver E, Chmiel A, Doran B, Boydell K. Encouraging help-seeking and engagement in a mental health app: what young people want. *Front Digit Health* 2022;4:1045765. PMID:36569870 doi:10.3389/fdgth.2022.1045765
- 24) Jebbink M. The motives of young adults to make use of mental health related apps in their daily lives -- a qualitative interview study [Master's thesis]. University of Twente; 2021. URL: https://essay.utwente.nl/86110/1/Jebbink_MA_BMS.pdf [accessed 2024-01-15]
- 25) Götzl C, Hiller S, Rauschenberg C, Schick A, Fichtelpeter J, Fischer Abaigar U, et al. Artificial intelligence-informed mobile mental health apps for young people: a mixed-methods approach on users' and stakeholders' perspectives. *Child Adolesc Psychiatry Ment Health* 2022;16:86. PMID:36357860 doi:10.1186/s13034-022-00516-4
- 26) Rickwood DJ, Mazzer KR, Telford NR. Social influences on seeking help from mental health services, in-person and online, during adolescence and young adulthood. *BMC Psychiatry* 2015;15:40. PMID:25886609 doi:10.1186/s12888-015-0429-6
- 27) Sawrikar V, Van Dyke C, Smith Slep AM. The Ws of parental help-seeking: when, where, and for what do parents seek help for child mental health. *Child Psychiatry Hum Dev* 2024. doi:10.1007/s10578-024-01683-5
- 28) Apolinário-Hagen J, Harrer M, Kählke F, Fritsche L, Salewski C, Ebert DD. Public attitudes toward guided internet-based therapies: web-based survey study. *JMIR Ment Health* 2018;5(2):e10735. PMID:29967003 doi:10.2196/10735
- 29) Christensen H, Griffiths KM, Farrer L. Adherence in internet interventions for anxiety and depression: systematic review. *J Med Internet Res* 2009;11(2):e13. PMID:19403466 doi:10.2196/jmir.1194

- 30) Melville KM, Casey LM, Kavanagh DJ. Dropout from Internet-based treatment for psychological disorders. *Br J Clin Psychol* 2010;49(4):455-471. PMID:19799804 doi:10.1348/014466509X472138
- 31) Gulliver A, Griffiths KM, Christensen H. Perceived barriers and facilitators to mental health help-seeking in young people: a systematic review. *BMC Psychiatry* 2010;10:113. PMID:21192795 doi:10.1186/1471-244X-10-113
- 32) Radovic A, Gmelin T, Stein BD, Miller E. Depressed adolescents' positive and negative use of social media. *J Adolesc* 2017;55:5-15. PMID:27997851 doi:10.1016/j.adolescence.2016.12.002